Mira Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.18next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly4.8MTarget: Sufficient capital to fund Phase 2a clinical trials and operations beyond Q1 2027
Research and Development (R&D) Expenses Quarterly524.8KTarget: Optimized and targeted R&D spending to advance core pipeline candidates
Net Loss Quarterly-1.2MTarget: Gradual reduction in operating losses through targeted R&D and administrative cost controls
Watch Items
- Ketamir-2 Phase 2a Clinical Trial ProgressTrigger: FDA acceptance and initiation of the Phase 2a trial for Chemotherapy-Induced Peripheral Neuropathy (CIPN)Action: Monitor patient enrollment, dosing safety, and initial efficacy readouts at the leading U.S. cancer center
- Going Concern and Capital RaisingTrigger: Cash runway projected to last only into the first quarter of 2027Action: Track dilutive equity offerings, strategic partnerships, or licensing agreements to secure necessary operational funding
- Preclinical Pipeline Milestones (MIRA-55 and SKNY-1)Trigger: IND filings and preclinical data updates for MIRA-55 (chronic inflammatory pain) and SKNY-1 (obesity/addiction)Action: Evaluate regulatory progress and potential co-development or sublicensing opportunities under the consolidated global rights structure
Research as of 19 Jun 2026